{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:38:03Z","timestamp":1782135483649,"version":"3.54.5"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Scientific and Technological Development Program","doi-asserted-by":"crossref","award":["YDZJ202401092ZYTS"],"award-info":[{"award-number":["YDZJ202401092ZYTS"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jilin Provincial Department of Education","award":["JJKH20230958KJ"],"award-info":[{"award-number":["JJKH20230958KJ"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Vorapaxar is a platelet protease-activated receptor-1 antagonist that can inhibit thrombin- and thrombin receptor agonist peptide-induced platelet aggregation. This study aims to explore the potential medication risks of vorapaxar through data mining of its related adverse events, thereby providing a more rational and safe reference for clinical medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, adverse event reports related to Vorapaxar were retrieved and extracted from the FAERS database covering the 2004 Q1to 2024 Q4. The primary method employed was the reporting odds ratio (ROR) approach, which was used to detect risk signals associated with Vorapaxar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 185 adverse event reports were included in this study, among which male cases accounted for 52%, higher than the proportion of female cases. Most reports were submitted by consumers, and the majority of these reports originated from the United States. Screening of Vorapaxar identified 162 preferred terms (PTs), most of which were consistent with the adverse reaction information of Vorapaxar already published by the U.S. Food and Drug Administration (FDA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The adverse events involved 19 organ systems. Reports on vascular diseases, neurological diseases, and other conditions were numerous with strong signals, which were consistent with the drug instructions. Among them, vascular diseases had the highest risk of positive signals, including various hemorrhagic events and vascular structural\/functional abnormalities. These findings suggest that clinical practice should be alert to adverse reactions in the vascular system, especially bleeding and severe vascular structural abnormalities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0340893","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:28:41Z","timestamp":1771007321000},"page":"e0340893","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis and mining of adverse events associated with vorapaxar: A FAERS database-based study"],"prefix":"10.1371","volume":"21","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4407-1765","authenticated-orcid":true,"given":"Yujuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"pone.0340893.ref001","doi-asserted-by":"crossref","first-page":"120045","DOI":"10.1016\/j.lfs.2021.120045","article-title":"Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function","volume":"286","author":"Z\u015e Aksoyalp","year":"2021","journal-title":"Life Sci"},{"issue":"18","key":"pone.0340893.ref002","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jacc.2022.08.767","article-title":"Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.","volume":"80","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"pone.0340893.ref003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CRD.0000000000000390","article-title":"Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar","volume":"30","author":"R Chaudhary","year":"2022","journal-title":"Cardiol Rev"},{"issue":"5","key":"pone.0340893.ref004","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1570161118666200820141131","article-title":"Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis","volume":"19","author":"M De Carlo","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"pone.0340893.ref005","article-title":"Efficacy and safety of antiplatelet therapy for secondary prevention of small subcortical infarction: A systematic review and network meta-analysis","author":"X Feng","year":"2025","journal-title":"Eur Stroke J"},{"issue":"12","key":"pone.0340893.ref006","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.3390\/cells10123517","article-title":"Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation","volume":"10","author":"J Friebel","year":"2021","journal-title":"Cells"},{"issue":"2","key":"pone.0340893.ref007","doi-asserted-by":"crossref","DOI":"10.1111\/xen.70041","article-title":"Defect in Sensing Human Thrombin by Porcine Endothelial Protease-Activated Receptor-1: Molecular Incompatibility Between Porcine PAR-1 and Human Thrombin","volume":"32","author":"TX Hoang","year":"2025","journal-title":"Xenotransplantation"},{"key":"pone.0340893.ref008","doi-asserted-by":"crossref","unstructured":"Gilchrist IC Jr, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, et al. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. J Am Heart Assoc. 2021;10(20):e021412. https:\/\/doi.org\/10.1161\/JAHA.121.021412 34622665","DOI":"10.1161\/JAHA.121.021412"},{"issue":"4","key":"pone.0340893.ref009","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/HEP.0000000000000401","article-title":"Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression","volume":"78","author":"R Maeso-D\u00edaz","year":"2023","journal-title":"Hepatology"},{"key":"pone.0340893.ref010","doi-asserted-by":"crossref","first-page":"1416985","DOI":"10.3389\/fphar.2024.1416985","article-title":"Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events","volume":"15","author":"L He","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"pone.0340893.ref011","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"10","key":"pone.0340893.ref012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26104497","article-title":"Molecular dynamics-guided repositioning of FDA-approved drugs for PD-L1 inhibition with in vitro anticancer potential","volume":"26","author":"D Jiang","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"7","key":"pone.0340893.ref013","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1021\/acs.jmedchem.1c02048","article-title":"Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early Discovery","volume":"65","author":"M Mandal","year":"2022","journal-title":"J Med Chem"},{"key":"pone.0340893.ref014","doi-asserted-by":"crossref","DOI":"10.1177\/10742484211056115","article-title":"Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease","volume":"27","author":"JT Morrison","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"5","key":"pone.0340893.ref015","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-0042-1760256","article-title":"The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease","volume":"123","author":"DWT Nilsen","year":"2023","journal-title":"Thromb Haemost"},{"key":"pone.0340893.ref016","doi-asserted-by":"crossref","unstructured":"Sedding D, Schmidt TM, B\u00e4hre H. Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). J JACC Adv. 2025;4(3):101590.","DOI":"10.1016\/j.jacadv.2025.101590"},{"key":"pone.0340893.ref017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2015.03.073","article-title":"Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist","volume":"758","author":"T-Q Cai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"pone.0340893.ref018","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1358863X19892690","article-title":"Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2\u00b0P-TIMI 50 trial","volume":"25","author":"A Qamar","year":"2020","journal-title":"Vasc Med"},{"issue":"21","key":"pone.0340893.ref019","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1111\/bph.15194","article-title":"Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19?","volume":"177","author":"K Sriram","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"5","key":"pone.0340893.ref020","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10557-023-07455-y","article-title":"The Impact of Convertase Subtilisin\/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia","volume":"38","author":"L Kone\u010dn\u00fd","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"pone.0340893.ref021","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12933-025-02891-6","article-title":"Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls","volume":"24","author":"M Pacl\u00edkov\u00e1","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"30","key":"pone.0340893.ref022","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41388-025-03421-0","article-title":"PAR1 inhibition sensitizes HPV-negative HNSCC cells to ferroptosis through inhibition of the STAT3-mediated regulation of iron and lipid metabolic pathways","volume":"44","author":"J Tian","year":"2025","journal-title":"Oncogene"},{"issue":"5","key":"pone.0340893.ref023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/fca-2019-0090","article-title":"Vorapaxar in the treatment of cardiovascular diseases","volume":"16","author":"US Tantry","year":"2020","journal-title":"Future Cardiol"},{"key":"pone.0340893.ref024","doi-asserted-by":"crossref","first-page":"101153","DOI":"10.1016\/j.neo.2025.101153","article-title":"Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression","volume":"63","author":"\u0130 Uslu-Bi\u00e7ak","year":"2025","journal-title":"Neoplasia"},{"issue":"12","key":"pone.0340893.ref025","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1586\/14779072.2015.1101343","article-title":"Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?","volume":"13","author":"VL Serebruany","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"pone.0340893.ref026","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2174\/1570161116666180117105339","article-title":"Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?","volume":"16","author":"N Spinthakis","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"pone.0340893.ref027","doi-asserted-by":"crossref","first-page":"115053","DOI":"10.1016\/j.expneurol.2024.115053","article-title":"Activation of PAR1 contributes to ferroptosis of Schwann cells and inhibits regeneration of myelin sheath after sciatic nerve crush injury in rats via Hippo-YAP\/ACSL4 pathway","volume":"384","author":"Z Wu","year":"2025","journal-title":"Exp Neurol"},{"issue":"7","key":"pone.0340893.ref028","first-page":"1580","article-title":"Dual Antiplatelet Therapy: A Concise Review for Clinicians","volume":"13","author":"HUH Virk","year":"2023","journal-title":"Life (Basel)"},{"key":"pone.0340893.ref029","doi-asserted-by":"crossref","first-page":"175438","DOI":"10.1016\/j.ejphar.2022.175438","article-title":"Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1\/JAK2\/STAT1\/3 signaling pathway-an experimental in vitro and vivo study","volume":"943","author":"T Xiao","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"pone.0340893.ref030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1358863X211042082","article-title":"No benefit of vorapaxar on walking performance in patients with intermittent claudication","volume":"27","author":"S Tsai","year":"2022","journal-title":"Vasc Med"},{"issue":"18","key":"pone.0340893.ref031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251810136","article-title":"Differential effect of omega-3 fatty acids on platelet inhibition by antiplatelet drugs in vitro","volume":"25","author":"IK Koutsaliaris","year":"2024","journal-title":"Int J Mol Sci"},{"key":"pone.0340893.ref032","doi-asserted-by":"crossref","first-page":"111508","DOI":"10.1016\/j.msec.2020.111508","article-title":"Vorapaxar-modified polysulfone membrane with high hemocompatibility inhibits thrombosis","volume":"118","author":"W Liu","year":"2021","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"21","key":"pone.0340893.ref033","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1042\/CS20200923","article-title":"The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis","volume":"134","author":"SWY Lok","year":"2020","journal-title":"Clin Sci (Lond)"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:28:46Z","timestamp":1771007326000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340893"}},"subtitle":[],"editor":[{"given":"Ufuk","family":"Demirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340893","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}